文献速递先天性心脏病外科

别嘌醇对法洛四联症心内修复术后结局的影响

Effect of administration of allopurinol on postoperative outcomes in patients undergoing intracardiac repair of tetralogy of Fallot.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-09-12

50例法洛四联症心内修复术患者随机分为别嘌醇组(n=25)和安慰剂组(n=25),评估术后正性肌力评分、机械通气时间、ICU停留、住院时间及血浆标志物。别嘌醇组正性肌力评分较低(11.04±5.70 vs 17.50±7.83;P=.02),ICU和住院时间较短,超氧化物歧化酶、白细胞介素1-β、白细胞介素6和丙二醛等生化标志物更有利。作者认为在推荐作为常规实践前需多场景进一步研究。

要点

  • 别嘌醇组正性肌力评分低于安慰剂组(11.04±5.70 vs 17.50±7.83;P=.02)。
  • 别嘌醇组ICU停留和住院时间低于安慰剂组。
  • 别嘌醇组术后白细胞介素1-β、白细胞介素6和丙二醛水平较低,超氧化物歧化酶水平较高。

核心结论

  • 法洛四联症心内修复术患者使用别嘌醇与正性肌力评分降低、机械通气时间缩短、ICU停留和住院时间缩短以及有利的炎症生化标志物相关。
  • 作者认为在推荐作为常规实践前需在多场景进一步研究。

研究设计与样本

  • 随机对照试验,50例接受法洛四联症心内修复术的患者随机分为别嘌醇组(n=25)和安慰剂组(n=25)。

主要发现

  • 正性肌力评分别嘌醇组低于安慰剂组(11.04±5.70 vs 17.50±7.83;P=.02)。
  • ICU停留和住院时间别嘌醇组低于安慰剂组。
  • 超氧化物歧化酶术前安慰剂组 vs 别嘌醇组为2.87±1.21 U/mL vs 4.5±2.08 U/mL(P=.012),主动脉阻断钳释放后为2.32±0.98 U/mL vs 5.32±2.81 U/mL(P<.001),体外循环结束后为2.18±1.0.78 U/mL vs 3.44±1.99 U/mL(P=.003),原文此处写作2.18±1.0.78 U/mL。
  • 术后白细胞介素1-β和白细胞介素6水平别嘌醇组较低。
  • 体外循环后丙二醛水平别嘌醇组较低(安慰剂组11.80±2.94 pg/mL vs 别嘌醇组9.16±3.02 g/mL;P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为在推荐作为常规实践前需在多场景进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine effects of allopurinol administration on outcomes following intracardiac repair of tetralogy of Fallot (TOF). MATERIALS AND METHODS: Fifty patients undergoing TOF repair were randomized to 2 groups of 25 each: the allopurinol group (n = 25) and the placebo group (n = 25). Postoperatively, inotropic score, rhythm, duration of mechanical ventilation, cardiac output, intensive care unit (ICU) stay, and hospital stay were assessed. Plasma troponin-I, superoxide dismutase (SOD), interleukin (IL) 1-ß, IL-6, and malondialdehyde were measured serially. RESULTS: Inotropic score was lower in the allopurinol compared with placebo group (11.04 ± 5.70 vs 17.50 ± 7.83; P = .02). Duration of ICU and hospital stay was lower in the allopurinol group. Plasma levels of SOD preoperative were (2.87 ± 1.21 U/mL vs 4.5 ± 2.08 U/mL; P = .012), immediately following release of crossclamp (2.32 ± 0.98 U/mL vs 5.32 ± 2.81 U/mL; P < .001), and after termination of CPB (2.18 ± 1.0.78 U/mL vs 3.44 ± 1.99 U/mL; P = .003) between the placebo versus allopurinol group, respectively. Postoperative levels of IL1-ß and IL-6 were lower in the allopurinol group. Malondialdehyde levels following CPB were lower in the allopurinol group (11.80 ± 2.94 pg/mL in the placebo vs 9.16 ± 3.02 g/mL in the allopurinol group; P < .001). CONCLUSIONS: Allopurinol administration in patients undergoing intracardiac repair of TOF is associated with reduced inotropic scores, duration of mechanical ventilation, ICU stay, and hospital stay and favorable biochemical markers of inflammation. Further studies in multiple setups are needed before recommending it as a routine practice.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Talwar S, Selvam MS, Makhija N, et al. Effect of administration of allopurinol on postoperative outcomes in patients undergoing intracardiac repair of tetralogy of Fallot. J Thorac Cardiovasc Surg. 2017. PMID: 29245201. doi:10.1016/j.jtcvs.2017.08.115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。